Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

High-dose vitamin D added to chemotherapy failed to provide a benefit in patients with metastatic colorectal cancer in the ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

This Comment is linked to The Lancet Haematology Series on Sexual Health in Patients with Haematological Malignancies; we ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

In 2021, GSK said the factory was likely to close in 2025 when its contract with Sandoz ceased "in the absence of any other ...

The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

TD Cowen maintained a Hold rating on GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), with a consistent price target of $1,790.00. The firm's stance comes after GlaxoSmithKline reported positive Phase ...